Novel diagnostic markers for periprosthetic joint infection: a systematic review
Frontiers in Cellular and Infection Microbiology · 17.07.2023 · 13
DOI: 10.3389/fcimb.2023.1210345 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 17.07.2023. Verfasst von Melanie Schindler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Trauma Surgery, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Prosthesis-Related Infections, Arthritis, Infectious, alpha-Defensins. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Identifying novel biomarkers that are both specific and sensitive to periprosthetic joint infection (PJI) has the potential to improve diagnostic accuracy and ultimately enhance patient outcomes. Therefore, the aim of this systematic review is to identify and evaluate the effectiveness of novel biomarkers for the diagnosis of PJI.
Methods
We searched the MEDLINE, EMBASE, PubMed, and Cochrane Library databases from January 1, 2018, to September 30, 2022, using the search terms “periprosthetic joint infection,” “prosthetic joint infection,” or “periprosthetic infection” as the diagnosis of interest and the target index, combined with the term “marker.” We excluded articles that mentioned established biomarkers such as CRP, ESR, Interleukin 6, Alpha defensin, PCT (procalcitonin), and LC (leucocyte cell count). We used the MSIS, ICM, or EBJS criteria for PJI as the reference standard during quality assessment.
Results
We collected 19 studies that analyzed fourteen different novel biomarkers. Proteins were the most commonly analyzed biomarkers (nine studies), followed by molecules (three studies), exosomes (two studies), DNA (two studies), interleukins (one study), and lysosomes (one study). Calprotectin was a frequently analyzed and promising marker. In the scenario where the threshold was set at ≥50-mg/mL, the calprotectin point-of-care (POC) performance showed a high sensitivity of 98.1% and a specificity of 95.7%.
Conclusion
None of the analyzed biomarkers demonstrated outstanding performance compared to the established parameters used for standardized treatment based on established PJI definitions. Further studies are needed to determine the benefit and usefulness of implementing new biomarkers in diagnostic PJI settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Trauma Surgery, University Hospital Regensburg, Regensburg, Germany.
- Department of Orthopaedic Surgery, University Hospital of Regensburg, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany.
- Nuffield Orthopaedic Centre, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.
Zitieren
APA
Schindler, M., Walter, N., Maderbacher, G., Sigmund, I. K., Alt, V., & Rupp, M. (2023). Novel diagnostic markers for periprosthetic joint infection: a systematic review. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1210345
Vancouver
Schindler M, Walter N, Maderbacher G, Sigmund IK, Alt V, Rupp M. Novel diagnostic markers for periprosthetic joint infection: a systematic review. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1210345
BibTeX
@article{Schindler2023,
author = {Schindler, Melanie and Walter, Nike and Maderbacher, Guenther and Sigmund, Irene K and Alt, Volker and Rupp, Markus},
title = {Novel diagnostic markers for periprosthetic joint infection: a systematic review},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1210345}
}
EUVIMED